ARXIS INC-A
ARXS · NASDAQ
Updated at 2026-10-13 14:04:20
- Today's High
- $49.08
- Today’s Low
- $45.93
%22%2F%3E%0A%3Cpath%20id%3D%22%26%23230%3B%26%23150%3B%26%23135%3B%26%23230%3B%26%23161%3B%26%23163%3B%26%23230%3B%26%23154%3B%26%23151%3B%26%23232%3B%26%23167%3B%26%23146%3B%22%20d%3D%22M48.3363%2013.4132H60.2082L46.795%205.72205e-06V11.8719C46.795%2012.7231%2047.4851%2013.4132%2048.3363%2013.4132Z%22%20fill%3D%22var(--fill-0%2C%20%23474741)%22%2F%3E%0A%3Cpath%20id%3D%22%26%23230%3B%26%23148%3B%26%23190%3B%26%23229%3B%26%23164%3B%26%23167%3B%26%23233%3B%26%23149%3B%26%23156%3B%22%20fill-rule%3D%22evenodd%22%20clip-rule%3D%22evenodd%22%20d%3D%22M11.3812%2020.3725C16.7977%2014.9559%2025.5803%2014.9559%2030.9969%2020.3725C36.413%2025.789%2036.4131%2034.5707%2030.9969%2039.9872C26.0109%2044.973%2018.1729%2045.3699%2012.7335%2041.1769L2.54298%2051.3684L0%2048.8254L10.1915%2038.6329C5.99993%2033.1937%206.39609%2025.3579%2011.3812%2020.3725ZM28.4539%2022.9155C24.4418%2018.9033%2017.9363%2018.9033%2013.9241%2022.9155C9.91245%2026.9275%209.91241%2033.4322%2013.9241%2037.4442C17.9362%2041.4562%2024.4418%2041.4562%2028.4539%2037.4442C32.4656%2033.4322%2032.4656%2026.9275%2028.4539%2022.9155Z%22%20fill%3D%22var(--fill-0%2C%20%235D5D56)%22%2F%3E%0A%3C%2Fg%3E%0A%20%20%3C%2Fsvg%3E%0A%3C%2Fsvg%3E%0A)
Candlestick trends are for reference. Refer to the trading page for actual data.
Key Statistics
- Previous Open
- $47.99
- Previous Close
- $47.78
- Volume
- 843.77K
- Market Cap
- $20.58B
- P/E Ratio
- --
- EPS
- --
Previous Day Range
52-Week Range
Company Overview
- Sector
- INDUSTRIALS
- Industry
- Aerospace & Defense
- Sub-industry
- AEROSPACE & DEFENSE
- Headquarters
- 1332 BLUE HILLS AVENUE, BLOOMFIELD, CT, UNITED STATES, 06002
- Country
- US
- Listing Date
- 2026-04-16
- Fiscal Year End
- December
- Shares Outstanding
- 417.47M
- CIK
- --
- Website
- www.arxis.com
Arxis, Inc. (ARXS) is a dynamic biotechnology company focused on developing cutting-edge therapeutics for complex diseases, leveraging a robust research and development framework. With a diverse drug pipeline targeting both rare and widespread conditions, Arxis emphasizes strategic partnerships and comprehensive clinical initiatives to drive innovation and improve patient outcomes. As it progresses through critical clinical trial phases, the company is well-positioned for substantial growth and value creation, making it an attractive proposition for institutional investors in the fast-evolving biotech sector.
Financial Metrics
Revenue
2026-06-30
$500.72M
2026-03-31
$458.85M
2025-06-30
$400.44M
2025-03-31
$380.07M
Operating Expenses
2026-06-30
$229.91M
2026-03-31
$124.34M
2025-06-30
$317.59M
2025-03-31
$319.87M
Net Income
2026-06-30
-$4.9M
2026-03-31
$53.3M
2025-06-30
-$29.25M
2025-03-31
-$4.32M
Net Profit Margin
2026-06-30
-0.98%
2026-03-31
11.61%
2025-06-30
-7.3%
2025-03-31
-1.13%
Earnings Per Share
2026-06-30
$0.08
2026-03-31
$0.12
2025-06-30
--
2025-03-31
--
Earnings Before Interest, Taxes, Depreciation, and Amortization
2026-06-30
$90.04M
2026-03-31
$164.49M
2025-06-30
$135.54M
2025-03-31
$110.42M
Effective Tax Rate
2026-06-30
-247.17%
2026-03-31
22.75%
2025-06-30
--
2025-03-31
--
| Item | 2026-06-30 | 2026-03-31 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|
| Revenue | $500.72M | $458.85M | $400.44M | $380.07M |
| Operating Expenses | $229.91M | $124.34M | $317.59M | $319.87M |
| Net Income | -$4.9M | $53.3M | -$29.25M | -$4.32M |
| Net Profit Margin | -0.98% | 11.61% | -7.3% | -1.13% |
| Earnings Per Share | $0.08 | $0.12 | -- | -- |
| Earnings Before Interest, Taxes, Depreciation, and Amortization | $90.04M | $164.49M | $135.54M | $110.42M |
| Effective Tax Rate | -247.17% | 22.75% | -- | -- |
FAQs
Risk Warning
Stock prices can be highly volatile and may rise or fall sharply in a short period. Digital asset and derivative products involve additional risks such as leverage and liquidity. Content on this page is for reference only and does not constitute investment advice. Product availability and access may vary by region and applicable regulations.